Renal failure and leukocytosis are predictors of a complicated course of clostridium difficile infection if measured on day of diagnosis by Bauer, MP et al.
S U P P L E M E N T A R T I C L E
Renal Failure and Leukocytosis Are Predictors
of a Complicated Course of Clostridium difﬁcile
Infection if Measured on Day of Diagnosis
Martijn P. Bauer,1,a Marjolein P. M. Hensgens,1,a Mark A. Miller,2 Dale N. Gerding,3,4 Mark H. Wilcox,5,6 Adam P. Dale,5
Warren N. Fawley,5 Ed J. Kuijper,1 and Sherwood L. Gorbach7,8
1Leiden University Medical Center, The Netherlands; 2Division of Infectious Diseases, Jewish General Hospital, McGill University, Montreal, Quebec,
Canada; 3Hines Veterans Affairs Hospital, 4Loyola University Chicago School of Medicine, Maywood, Illinois; 5Department of Microbiology, The
General Inﬁrmary, Old Medical School, 6Leeds Institute of Molecular Medicine, University of Leeds, United Kingdom; 7Optimer Pharmaceuticals, Inc.,
San Diego, California, and 8Tufts University School of Medicine, Boston, Massachusetts
Nonsevere Clostridium difﬁcile infection (CDI) and severe CDI, which carries a higher risk than nonsevere CDI
for treatment failure and CDI recurrence, are difﬁcult to distinguish at the time of diagnosis. To investigate the
prognostic value of 3 markers of severe CDI suggested by recent guidelines (fever, leukocytosis, and renal
failure), we used the database of 2 randomized controlled trials, which contained information for 1105 patients
with CDI. Leukocytosis (risk ratio [RR], 2.29; 95% conﬁdence interval [CI], 1.63–3.21) and renal failure (RR,
2.52; 95% CI, 1.82–3.50) were associated with treatment failure. Fever, although associated with treatment
failure (RR, 2.45; 95% CI, 1.07–5.61), was rare. Renal failure was the only signiﬁcant predictor of recurrence
(RR, 1.45; 95% CI, 1.05–2.02). Different timing of measurements of leukocyte count and serum creatinine level
around the CDI diagnosis led to a different severity classiﬁcation in many cases. In conclusion, both leukocyto-
sis and renal failure are useful predictors, although timing of measurement is important.
Clostridium difﬁcile infection (CDI) has become an
increasing problem in many hospitals in the Western
world during the past decade. C. difﬁcile causes diar-
rhea and colitis, with a tendency to recur after initially
successful antimicrobial therapy. Furthermore, gut
inﬂammation may be so severe that antimicrobial thera-
py is not effective; in such cases, complications such
as hypotension, perforation, and toxic megacolon may
develop. Several risk factors for CDI have been identi-
ﬁed, of which the use of antibiotics is the most impor-
tant. Predicting which patients are at risk for developing
complications or recurrences can guide the choice and
duration of therapy. In 2009, a prediction rule for
recurrences, incorporating age, comorbid conditions,
and the necessity to continue inciting antibiotic therapy,
was published [1]. This rule was derived from and was
validated in 2 cohorts of 44 and 64 patients, respect-
ively. The relatively small sample sizes challenge the
credibility of this rule. Several risk factors for compli-
cations of CDI and prediction rules based on these
factors have been described, but unfortunately, none
of these prediction rules have been validated [2–6].
The choice of an appropriate end point for a predic-
tion rule for complicated and/or recurrent CDI has
been problematic. The clinical judgment of whether to
attribute end points such as CDI-related mortality and
intensive care unit admission may be highly subjective,
especially for elderly patients, who are often admitted
with severe illness and usually have signiﬁcant comor-
bid conditions. End points concerning the resolution
and recurrence of diarrhea need a precise deﬁnition of
diarrhea and quantitative measurement of stool volume
and frequency, which may be difﬁcult to obtain.
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Furthermore, the parameters included in a prediction rule
should be objective, routinely measured in clinical practice,
and available at the moment the rule is applied (ie, when CDI
is diagnosed).
A recent guideline by the Society for Healthcare Epidemiol-
ogy of America and the Infectious Diseases Society of
America recommends that age, peak leukocyte count, and
peak serum creatinine level be taken into account as potential
indicators of a complicated course of CDI when treatment is
started [7]. The European Society for Clinical Microbiology
and Infectious Diseases has issued a guidance document for
the treatment of CDI that also lists qualitative and quantitative
symptoms, signs, laboratory parameters, and radiological ﬁnd-
ings that may reﬂect more severe disease with associated
higher risk for complications and recurrences [8]. Three quan-
titative parameters for diagnosing severe colitis were included:
body temperature >38.5°C, leukocyte count >15 × 109/L, and
serum creatinine level >50% above baseline; however, these
cutoffs have not been conﬁrmed prospectively.
In the present study, we sought to investigate the value of 3
quantitative severity criteria in predicting the failure of antimi-
crobial therapy and the recurrence of CDI after initially suc-
cessful treatment. Furthermore, we aimed to investigate
whether leukocyte count and serum creatinine level ﬂuctuate
early in the course of a CDI episode and therefore whether the
timing of their measurements can inﬂuence whether severity
criteria are met. For our analyses, we used the database from 2
large randomized clinical trials that used a strict objective deﬁ-
nition of diarrhea and the database of a prospective single-
center cohort study that recorded sequential leukocyte counts
and serum creatinine levels around the date of CDI diagnosis.
METHODS
Databases
The database from 2 randomized controlled phase III trials
comparing vancomycin with ﬁdaxomicin for the treatment of
CDI was used to assess the predictive value of fever, leukocyte
count, and serum creatinine level [9, 10]. Patients were
recruited in the United States, Canada, and Europe (Clinical-
Trials.gov registry number NCT00314951, April 2006–July
2008, United States and Canada; and ClinicalTrials.gov
registry number NCT00468728, April 2007–November 2009,
United States, Belgium, Canada, France, Germany, Italy,
Spain, Sweden, and United Kingdom). Patients with CDI,
deﬁned on the basis of diarrhea (>3 unformed bowel move-
ments [UBMs] per day) and a positive stool toxin test for
C. difﬁcile, were randomly assigned to receive 125 mg of van-
comycin 4 times daily or 200 mg of ﬁdaxomicin twice daily
for 10 days. The numbers and times of UBMs were recorded
during treatment and for 2 days after an end-of-therapy visit.
For patients with rectal collection devices, volume was
converted to number of UBMs by dividing the volume by 60 mL
and rounding up to the nearest whole number. At the end-of-
therapy visit, an investigator assessed the success of therapy.
Clinical failure was deﬁned as the persistence of diarrhea, the
need for additional therapy for CDI, or both on the basis of
the opinion of the investigator [10]. Recurrence of CDI (deter-
mined by use of the same criteria as for enrollment [ie, >3
UBMs per 24 hours and a positive stool toxin test result]) was
assessed during the mean follow-up duration (±SD) of 28 ± 2
days after completion of therapy. At enrollment, temperature,
leukocyte count, and serum creatinine level were collected.
To assess whether the timing of laboratory measurements
could inﬂuence their prognostic value, we used the database of
a prospective cohort study performed at Leeds Teaching Hos-
pital in 2007. In this database, 104 consecutive adult inpatients
with CDI (deﬁned on the basis of the presence of unformed
stool and a positive C. difﬁcile toxin test result) were included.
On days −3 to +3 relative to day 0 (the day the diarrheal
sample was collected), leukocyte count and serum creatinine
level were recorded. Data from a minimum of 2 leukocyte
counts and creatinine levels on different days were required
for patients to be included in the analyses.
In both analyses, we deﬁned fever as a core body tempera-
ture >38.5°C and leukocytosis as a leukocyte count >15 × 109
leukocytes/L. Because the pre-CDI serum creatinine level was
not known for each patient, we substituted the 50% creatinine
level increase with a ﬁxed value of the creatinine level
>133 μmol/L (>1.5 mg/dL). This served as a proxy for renal
failure.
Analyses
The intention-to-treat population that received at least 1 dose
of study medication was used for the analysis. Distributions of
the continuous variables of temperature, leukocyte count, and
creatinine level were compared for patients with and patients
without clinical treatment failure and recurrence. Nonnor-
mally distributed variables were compared with the Mann-
Whitney U test. Proportions were compared with the χ2 test.
Risk ratios (RRs) and 95% conﬁdence intervals (CIs) were cal-
culated for the associations of fever, leukocytosis, and renal
failure with the outcome parameters. Kaplan-Meier survival
curves were constructed to investigate the association of fever,
leukocytosis, and renal failure with the time to resolution of
diarrhea (expressed in hours from the ﬁrst dose of ﬁdaxomicin
or vancomycin). The log-rank test was used to test the differ-
ence between the survival curves. Cox regression was used to
calculate hazard ratios (HRs) with 95% CIs. Receiver operating
characteristic curves were constructed to assess the validity of
the cutoffs used to deﬁne categorical variables. Variability of
leukocyte counts and serum creatinine levels were compared
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within patients and expressed in absolute differences. All ana-
lyses were carried out in SPSS for Windows software, version
17.0 (SPSS, Chicago, IL).
RESULTS
There were 1105 patients with CDI in the clinical trial data-
base. Patients treated with vancomycin (n = 566) or ﬁdaxomi-
cin (n = 539) had similar median values for temperature,
leukocyte count, and serum creatinine level and were evenly
distributed across the groups with respect to dichotomized
continuous variables (data not shown). Fever was rare; only
1.2% of patients (13 of 1102) had a temperature >38.5°C. The
median treatment duration was 11 days for each group.
Overall, 143 patients (13%) experienced clinical treatment
failure at the end of treatment. Of the 962 patients who were
cured after treatment, 194 (20%) experienced recurrence a
mean (±SD) of 28 ± 2 days after treatment.
The median leukocyte count and creatinine level were sig-
niﬁcantly higher in patients with clinical treatment failure;
temperature distributions in patients with and those without
treatment failure were almost identical. In addition, dichoto-
mous categories of fever, leukocytosis, and renal failure all
showed signiﬁcant correlation with treatment failure (Table 1).
The median creatinine level was signiﬁcantly higher in patients
with recurrence, and this parameter was the only signiﬁcant
predictor of recurrence (Table 2). Different cutoffs for the con-
tinuous variables of temperature, leukocyte count, and creati-
nine level, assessed by receiver operating characteristics, did not
lead to higher relative risks and therefore better performance in
the prediction of clinical treatment failure or recurrent CDI.
The probability of resolution of diarrhea within 10 days of
treatment was slightly lower in patients with renal failure,
compared with patients without renal failure (HR, 0.83; 95%
CI, .68–1.02; Figure 1). Neither fever (HR, 1.08; 95% CI,
.61–1.91) nor leukocytosis (HR, 1.02; 95% CI, .84–1.24) was
associated with a lower probability of resolution of diarrhea.
Although creatinine level distributions were similar between
patients treated with ﬁdaxomicin and those treated with van-
comycin, we repeated the analysis of renal failure as a predic-
tor of resolution of diarrhea stratiﬁed according to treatment
group and found similar results (vancomycin: HR, 0.80 [95%
CI, .61–1.05]; ﬁdaxomicin: HR, 0.88 [95% CI, .66–1.19]).
Because recurrences occurred less often in patients treated
with ﬁdaxomicin, the CI is widest in that group.
Clinical treatment failure rates were similar in the ﬁdaxomicin
and vancomycin treatment groups regardless of clinical status,
using the 3 severity factors. Recurrence was signiﬁcantly more
frequent following vancomycin treatment, compared with ﬁdax-
omicin treatment. In patients without renal failure, 93 of 402
patients (23.1%) cured by vancomycin therapy had a recurrence,
whereas only 56 of 403 (13.9%) experienced a recurrence after
successful ﬁdaxomicin treatment (P < .001). In patients with
renal failure at baseline, ﬁdaxomicin therapy was associated with
a 60% reduction in the frequency of recurrences (8 of 54
[14.8%]) relative to vancomycin (24 of 65 [36.9%]; P = .007).
Likewise, in patients categorized as having leukocytosis or severe
CDI, the incidence of recurrence was more than double for
patients cured with vancomycin, compared with those treated
successfully with ﬁdaxomicin (P < .01 for each comparison).
Because leukocytosis and renal failure at the time of diagno-
sis were shown to be the strongest predictors, we investigated
the stability of these parameters during a 6-day interval
around diagnosis. In the population from the database of
Leeds Teaching Hospital, the highest mean leukocyte count
(13.4 × 109 leukocytes/L) was found on the day of CDI diagno-
sis. Within the interval from 3 days before to 3 days after the
diagnosis of CDI, the mean difference between the highest
and lowest leukocyte counts was 6.4 × 109 leukocytes/L.
Twenty of 86 patients (23.3%) had a minimum to maximum
leukocyte count range >10 × 109 leukocytes/L, and 33 (38.4%)
Table 1. Determinants of Clinical Treatment Failure Among
Patients With Clostridium difﬁcile Infection
Variable Median Value IQR Pa
Continuous, outcome
Temperature (°C)
Failure 36.8 36.4–37.2 .180
Cure 36.7 36.4–37.1
Leukocyte count (×109 leukocytes/L)
Failure 10.5 6.8–17.4 .002
Cure 8.9 6.5–12.1
Creatinine level (μmol/L)b
Failure 80 62–150 .005
Cure 71 62–97
Categorical, cutoff Failurec RRd 95% CI
Fever, temperature
>38.5°C 4/13 2.45 1.07–5.61
≤38.5°C 137/1089
Leukocytosis, leukocyte level
>15 × 109 leukocytes/L 38/153 2.29 1.63–3.21
≤15 × 109 leukocytes/L 90/829
Renal failure, creatinine level
≥133 μmol/Lb 41/160 2.52 1.82–3.50
<133 μmol/Lb 91/896
Abbreviations: CI, confidence interval; IQR, interquartile range; RR, risk ratio.
a Comparison between patients with clinical treatment failure and those with
clinical cure.
b Creatinine conversion: 1 μmol/L is equal to 0.0113 mg/dL. Therefore,
133 μmol/L is equal to 1.50 mg/dL.
c Data are no. of patients with failure/overall no.
d For the association with failure.
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patients had a minimum to maximum leukocyte count range
that included the cutoff of 15 × 109 leukocytes/L; therefore, a
difference in timing of a single blood sample around diagnosis
could have led to a different severity classiﬁcation. The mean
serum creatinine concentration was 147 μmol/L on the day of
diagnosis. The mean minimum to maximum range in serum
creatinine values was 38.7 μmol/L. Nineteen of 93 patients
(20.4%) had a minimum to maximum range in creatinine levels
that included the cutoff of 133 μmol/L, which could have led
to a different classiﬁcation in the case of different timing.
DISCUSSION
Leukocytosis and renal failure were signiﬁcant predictors of
failure of CDI treatment. Only renal failure showed a trend
toward longer duration of diarrhea during treatment and was
correlated signiﬁcantly with recurrence after successful treat-
ment. Both leukocyte count and serum creatinine level were
highly variable around diagnosis. Fever was found to be too
infrequent in our study to be a useful predictor, but its associ-
ated relative risk was signiﬁcant.
In previous studies, leukocytosis and renal failure were also
associated with complications and recurrence of CDI [3, 11–13].
Therefore, both parameters could be suitable for evaluation in
a prediction model. However, because of the variable nature of
these values around the time of CDI diagnosis, a strict deﬁ-
nition is needed before incorporating these parameters in a
prediction rule. Early or late diagnosis could inﬂuence leuko-
cyte count and serum creatinine level. Fever appeared not to
be a useful predictor of failure of CDI treatment. This was also
shown by a small study in 2007 [14].
Both fever and leukocytosis are thought to reﬂect more severe
inﬂammation of the bowel wall. However, fever was too rare in
our patient population to be of use as a predictor. Renal failure
may reﬂect loss of effective circulating volume due either to
dehydration because of diarrhea or to shock in the context of a
systemic inﬂammatory response. Unfortunately, the predictive
value of these parameters may decrease because of underlying
illnesses and comorbid conditions. Renal failure was present in
14% of clinical patients and was the only signiﬁcant predictor of
recurrence, and it was the only parameter associated, albeit non-
signiﬁcantly, with a longer time to resolution of diarrhea. Thus,
creatinine level may be a good predictor, also because of its rela-
tively greater stability around the time of CDI diagnosis in com-
parison to leukocytosis.
Strengths of this study are the large number of patients with
CDI in the database with a well-described deﬁnition of
Figure 1. Kaplan-Meier analysis of time to resolution of diarrhea for
patients with and without renal failure. The hazard ratio was 0.83 (95%
conﬁdence interval, .68–1.02).
Table 2. Determinants of Clostridium difﬁcile Infection
Recurrence
Variable Median Value IQR Pa
Continuous, outcome
Temperature (°C)
No recurrence 36.7 36.4–37.1 .827
Recurrence 36.7 36.4–37.0
Leukocyte count (×109 leukocytes/L)
No recurrence 8.8 6.5–12.1 .276
Recurrence 9.1 6.6–12.8
Creatinine level (μmol/L)b
No recurrence 71 62–97 .008
Recurrence 80 62–115
Categorical, cutoff Recurrencec RRd 95% CI
Fever, temperature
>38.5°C 1/9 0.55 .09–3.51
≤38.5°C 192/952
Leukocytosis, leukocyte level
>15 × 109 leukocytes/L 22/115 1.00 .67–1.50
≤15 × 109 leukocytes/L 141/739
Renal failure, creatinine level
≥133 μmol/Lb 32/119 1.45 1.05–2.02
<133 μmol/Lb 149/805
Abbreviations: CI, confidence interval; IQR, interquartile range; RR, risk ratio.
a Comparison between patients with recurrence and those without
recurrence.
b Creatinine conversion: 1 μmol/L is equal to 0.0113 mg/dL. Therefore,
133 μmol/L is equal to 1.50 mg/dL.
c Data are no. of patients with recurrence/overall no.
d For the association with recurrence.
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diarrhea and a consistent measure of UBMs. One limitation is
that other potential predictors of severe CDI, such as age,
serum albumin level, or use of concomitant antibiotics, were
not included in this analysis. Therefore, we were not able to de-
velop a complete risk score. Another limitation is the absence
of a baseline creatinine level for each patient, precluding us
from distinguishing between chronic and acute renal failure.
The results of our study suggest that both leukocytosis and
renal failure predict clinical treatment failure, whereas only
renal failure is a predictor of recurrence after therapy. However,
these predictors are highly dependent on the timing of their
determination, hampering their use in clinical practice. We
need better and more closely deﬁned predictors to construct a
reliable prediction score for complicated and recurrent CDI
that is applicable in clinical practice.
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